FindMyRecallSubscribe
Class II: temporary or reversible health riskTerminated

Sandoz Transderm Scop Recall

Transderm Scop (scopolamine) Transdermal System, 1

Sandoz Inc · Princeton, NJ

Risk level
Class II
Reported by FDA
Mar 1, 2017
Recall ID
D-0481-2017
Check your lot numberHow we source this data

Summary

Sandoz recalled Transderm Scop starting Feb 2, 2017. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-0481-2017 on Mar 1, 2017. Reason: Labeling: Incorrect Instructions:outer carton contains the incorrect instructions for Step 2 stating "Do cut the patch" rather than the correct instructions of "Do not cut the patch". The pouch containing the patch is labeled correctly. Status: Terminated.

Why it was recalled

Labeling: Incorrect Instructions:outer carton contains the incorrect instructions for Step 2 stating "Do cut the patch" rather than the correct instructions of "Do not cut the patch". The pouch containing the patch is labeled correctly.

Product description

Transderm Scop (scopolamine) Transdermal System, 1.5 mg, 1 patch per pouch (NDC 66758-208-58), packaged in 4-count patches per carton (NDC 66758-208-54), Rx Only, Manufactured by ALZA Corporation, Vacaville, CA 95688 for Sandoz Inc., Princeton, NJ 08540.

Lot numbers, UPCs & expiration codes

Lot #: 6323Q11, 6328Q11, Exp 06/19; 6355Q11, Exp 07/19

Where it was sold

Nationwide in the USA and Puerto Rico

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0481-2017
Classification
Class II
Status
Terminated
Recall initiated
Feb 2, 2017
FDA report date
Mar 1, 2017
Quantity
157,922 cartons
Recall type
Voluntary: Firm initiated
Recalling firm
Sandoz Inc

Original FDA data

Every field from FDA enforcement report D-0481-2017, exactly as published.

Show all FDA fields
City
Princeton
State
NJ
Status
Terminated
Country
United States
Event ID
76435
Address
100 College Rd W
Code information
Lot #: 6323Q11, 6328Q11, Exp 06/19; 6355Q11, Exp 07/19
Postal code
08540-6604
Report date
Mar 1, 2017
Product type
Drugs
Recall number
D-0481-2017
Classification
Class II
Recalling firm
Sandoz Inc
Product quantity
157,922 cartons
Termination date
Oct 24, 2017
Reason for recall
Labeling: Incorrect Instructions:outer carton contains the incorrect instructions for Step 2 stating "Do cut the patch" rather than the correct instructions of "Do not cut the patch". The pouch containing the patch is labeled correctly.
Voluntary / mandated
Voluntary: Firm initiated
Product description
Transderm Scop (scopolamine) Transdermal System, 1.5 mg, 1 patch per pouch (NDC 66758-208-58), packaged in 4-count patches per carton (NDC 66758-208-54), Rx Only, Manufactured by ALZA Corporation, Vacaville, CA 95688 for Sandoz Inc., Princeton, NJ 08540.
Distribution pattern
Nationwide in the USA and Puerto Rico
Recall initiation date
Feb 2, 2017
Initial firm notification
Letter
Center classification date
Feb 17, 2017

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0481-2017, published Mar 1, 2017. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls